These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 3534616)

  • 1. [Bone marrow graft: graft versus host reaction and rejection].
    Fischer A; Griscelli C
    Nephrologie; 1986; 7(3 Suppl):1-4. PubMed ID: 3534616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of graft-versus-host reactivity, lymphocyte depletion, and cell dose on allogeneic bone marrow engraftment.
    Glass B; Uharek L; Gaska T; Gassmann W; Löffler H; Müller-Ruchholtz W
    Bone Marrow Transplant; 1993; 12 Suppl 3():S41-7. PubMed ID: 8124257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic bone marrow transplantation: relation between chimaerism and immunity.
    Vossen J
    Verh K Acad Geneeskd Belg; 1998; 60(2):111-43; discussion 143-5. PubMed ID: 9703764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Graft versus host reaction and hybrid resistance in experimental models and clinical practice].
    Clerici M; Villa ML; Clerici E
    Boll Ist Sieroter Milan; 1988; 67(3):177-96. PubMed ID: 3072013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Use of monoclonal antibodies for the prevention of graft-versus-host and host-versus-graft reaction in allogenic bone marrow grafts].
    Hervé P
    Nephrologie; 1987; 8(3):103-8. PubMed ID: 3309699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The graft-versus-host reaction and immune function. III. Functional pre-T cells in the bone marrow of graft-versus-host-reactive mice displaying T cell immunodeficiency.
    Seddik M; Seemayer TA; Lapp WS
    Transplantation; 1986 Feb; 41(2):238-42. PubMed ID: 3484849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graft vs graft reaction resulting in the elimination of maternal cells in a SCID patient with maternofetal GVHd after an HLA identical bone marrow transplantation.
    Le Deist F; Raffoux C; Griscelli C; Fischer A
    J Immunol; 1987 Jan; 138(2):423-7. PubMed ID: 3540121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of polyinosinic:polycytidylic acid (pI:C) on the graft-vs-host (GVH) reaction. II. Increased NK-mediated rejection on C57BL/6 lymphocytes by (C57BL/6 X A)F1 mice.
    Peres A; Nestel FP; Seemayer TA; Lapp WS
    J Immunol; 1986 Dec; 137(11):3420-7. PubMed ID: 3537120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous protection against allograft rejection and graft-versus-host disease after total lymphoid irradiation: role of natural killer T cells.
    Liu YP; Li Z; Nador RG; Strober S
    Transplantation; 2008 Feb; 85(4):607-14. PubMed ID: 18347541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The graft-versus-host reaction and immune function. II. Recruitment of pre-T-cells in vivo by graft-versus-host-induced dysplastic thymuses following irradiation and bone marrow treatment.
    Seddik M; Seemayer TA; Lapp WS
    Transplantation; 1984 Mar; 37(3):286-90. PubMed ID: 6142550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
    Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
    Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
    Michallet M; Dhedin N; Michallet AS
    Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation.
    Truitt RL; Johnson BD; Hanke C; Talib S; Hearst JE
    J Immunol; 1999 Nov; 163(9):5145-56. PubMed ID: 10528221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
    Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
    Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.
    Keever-Taylor CA; Passweg J; Kawanishi Y; Casper J; Flomenberg N; Baxter-Lowe LA
    Bone Marrow Transplant; 1997 May; 19(10):1001-9. PubMed ID: 9169644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-stimulated/Tc2 cells abrogate murine marrow graft rejection.
    Erdmann AA; Jung U; Foley JE; Toda Y; Fowler DH
    Biol Blood Marrow Transplant; 2004 Sep; 10(9):604-13. PubMed ID: 15319772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.